Table II.

Home-based telemedicine systems used in advanced stages of Parkinson's disease.

Author	Year	Evidence type	Method	Treatment	Outcome	(Refs.)
Willows et al	2017	Observational study	Nasojejunal tube placed during fluoroscopic passive/active positioning, with radiological confirmation of placement	LCIG delivery initiated through telemedicine over a 16-h period: total morning 5-10 ml (100-200 mg levodopa) to 20 ml max; median time for titration 2.8 days	Technically achievable, a well-tolerated alternative method	(12)
Evans et al	2020	Pilot Study	Phone consultations in virtual clinic combined with a report from a Parkinson's KinetiGraph	-	Acceptable for most patients, timesaving, in need of further cost analysis	(13)
Hssayeni et al	2019	Comparative Study	Wearable sensors combined with gradient tree boosting or with a deep learning model based on LSTM networks	-	Highest correlation for gradient tree boosting; solid approach for assessing tremor severity	(14)
Cilia et al	2020	Observational Study	Remote telenursing assistance service ‘Parkinson Care’ and video-consultations on Microsoft teams® platform	-	Introduction of a new element (case managers, not initially part of patient's care team); development of triage algorithm	(15)
Beck et al	2017	Randomized controlled trial	Usual care by a physician compared to 4 virtual consults by a remote neurologist added to usual care	-	Virtual care was achievable with no major differences in quality of life and burden	(16)

LCIG, levodopa-carbidopa intestinal gel; LSTM, long short-term memory.